iBio Q1 2026 Results: Net Loss of $7.6M, Loss Widens
For the quarter ended September 30, 2026, iBio reported revenue of $1.075 million, a significant increase from $100,000 in the prior year. However, net loss widened to $7.551 million compared to $5.720 million in 2025, primarily driven by a nearly 90% increase in research and development expenses.
- Key figure
- Net loss $7.6M